Business Context and Reporting Period
Company: Incyte Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: Incyte is a drug discovery and development company focused on proprietary small molecule drugs for HIV, diabetes, oncology, and inflammation. The company has no commercial product sales and relies on collaboration agreements (notably with Pfizer) and licensing revenues.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 2007 | 9 Months Ended Sep 30, 2007 | 9 Months Ended Sep 30, 2006 |
|---|---|---|---|
| Total Revenues | $6,690 | $24,688 | $20,587 |
| Net Loss | $(24,494) | $(65,080) | $(53,663) |
| Loss Per Share (Basic/Diluted) | $(0.29) | $(0.77) | $(0.64) |
| Operating Cash Flow | N/A | $(65,150) | $(28,185) |
| Cash & Cash Equivalents | $95,629 | $95,629 | $115,921 |
| Total Marketable Securities | $170,232 | $170,232 | $310,949 |
| Total Debt (Convertible Notes) | $377,503 | $377,503 | $371,103 |
| Stockholders' Deficit | $(141,473) | $(141,473) | $(84,908) |
Note: Debt figures represent the carrying value of Convertible Senior Notes ($120,076) and Convertible Subordinated Notes ($257,427) as of September 30, 2007.
Material Changes vs. Prior Period
- Revenue: Total revenue for the nine months ended September 30, 2007, increased 20% to $24.7 million from $20.6 million in the prior year. This was driven by a $3.0 million milestone payment from Pfizer and continued recognition of the upfront fee from the Pfizer collaboration.
- Net Loss: Net loss widened to $65.1 million for the nine-month period compared to $53.7 million in 2006. The increase is primarily due to higher Research and Development (R&D) expenses ($72.3 million vs. $64.0 million) and increased interest expense ($17.9 million vs. $11.8 million) due to accretion on convertible notes issued in late 2006.
- Liquidity: Cash and cash equivalents increased significantly from $18.9 million at year-end 2006 to $95.6 million at September 30, 2007, largely due to net cash provided by investing activities ($140.9 million) from the sale and maturity of marketable securities.
- Other Expenses: Other expenses turned from a $3.1 million charge in the prior year to a $0.5 million credit in the current period, primarily due to the absence of a $3.4 million litigation settlement fee paid in June 2006.
Guidance, Outlook, and Risks
- Outlook: Management anticipates incurring additional losses for several years as it expands drug discovery and development programs. The company expects to rely on cash, cash equivalents, and marketable securities (totaling $265.9 million as of September 30, 2007) to fund operations for at least the next twelve months.
- Pipeline Status: Key programs include CCR5 antagonists for HIV (Phase II), 11-beta HSD1 inhibitors for Type 2 Diabetes (Phase IIa), and JAK inhibitors for myelofibrosis and rheumatoid arthritis (Phase IIa). Two oncology programs are expected to progress to clinical development in the first half of 2008.
- Collaboration Dependence: A significant portion of revenue is derived from the collaboration with Pfizer. One customer contributed 85% of revenues for the nine months ended September 30, 2007.
- Risks:
- Capital Needs: The company has a history of operating losses and an accumulated deficit of $978.6 million. It may need to raise additional capital, which could be dilutive or restrictive.
- Debt Obligations: Significant debt service obligations exist for convertible senior and subordinated notes. Failure to generate cash flow or raise capital could force the liquidation of marketable securities.
- Regulatory & Development Risk: Drug development is lengthy and expensive. There is no assurance that clinical trials will succeed or that regulatory approval will be obtained.
- Subsequent Event: In October 2007, Pfizer purchased an additional $10.0 million convertible subordinated note.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $265.9 million in liquid assets against projected R&D burn rates and debt service requirements.
- Pfizer Collaboration: Assess the stability of the Pfizer agreement, which accounts for the vast majority of revenue, and the likelihood of future milestone payments.
- Debt Structure: Review the terms of the $411.8 million in aggregate principal debt, specifically conversion prices and maturity dates (2011 and 2013).
- Clinical Milestones: Monitor the progress of Phase II trials for HIV, Diabetes, and Oncology candidates, as failure here would severely impact future valuation.
- Restructuring Accruals: Review the remaining accruals for lease commitments and restructuring costs ($18.2 million total as of September 30, 2007) for potential future cash outflows.